Literature DB >> 10404803

Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial.

G Stacher1, G Schernthaner, M Francesconi, H P Kopp, H Bergmann, G Stacher-Janotta, U Weber.   

Abstract

In insulin-dependent diabetes mellitus, slow gastric emptying may make absorption unpredictable and foster glycemic instability. Cisapride accelerates emptying, but controlled long term studies are scarce, and effects on glycemic control unknown. We investigated, in patients with insulin-dependent diabetes mellitus and unstable glycemia, the effects of 10 mg cisapride 4 times daily for 8 weeks vs. placebo on glycemic control and gastric emptying under random, cross-over, double blind conditions. In 14 patients with delayed and 9 with nondelayed emptying, blood glucose variability over 28-week treatment periods separated by a 4-week wash-out and gastric emptying of a semisolid 1168-kJ meal immediately after the treatment periods were assessed. Cisapride did not affect glycemic control [SD of within-patient mean blood glucose, 4.2 mmol/L +/-0.1 (+/- SEM) vs. 4.0+/-0.1 mmol/L after placebo; hemoglobin A1c, 8.3+/-0.2% vs. 8.5+/-0.2%]. Emptying was faster after cisapride than after placebo in 8 of 14 patients with delayed vs. 7 of 9 with nondelayed emptying (P = NS) and in 11 of 15 without vs. 4 of 8 with cardiovascular autonomic neuropathy (P = NS). Autonomic neuropathy prevailed in 7 of 14 patients with delayed and 1 of 9 with nondelayed emptying. Blood glucose immediately before and during assessment of emptying was unrelated to the emptying rate, whereas blood glucose increases over fasting levels were greater with faster emptying (P<0.002). In conclusion, cisapride's effects were not different from those of placebo on glycemic control and gastric emptying, it did not differently affect patients with delayed vs. nondelayed emptying, and it slightly accelerated emptying (P = NS) in patients without, but not in those with, cardiovascular autonomic neuropathy. Blood glucose levels before and during assessment of emptying did not affect emptying, but the glucose rise over fasting levels was greater with faster emptying.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404803     DOI: 10.1210/jcem.84.7.5859

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Gastroparesis: current concepts and management.

Authors:  Tatsuhiro Masaoka; Jan Tack
Journal:  Gut Liver       Date:  2009-09-30       Impact factor: 4.519

Review 2.  Gastroparesis--current concepts and considerations.

Authors:  William L Hasler
Journal:  Medscape J Med       Date:  2008-01-23

Review 3.  Childhood gastroparesis is a unique entity in need of further investigation.

Authors:  Liz Febo-Rodriguez; Bruno P Chumpitazi; Robert J Shulman
Journal:  Neurogastroenterol Motil       Date:  2019-08-13       Impact factor: 3.598

4.  Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.

Authors:  Gopanandan Parthasarathy; Yogish C Kudva; Phillip A Low; Michael Camilleri; Ananda Basu; Adil E Bharucha
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

5.  Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial.

Authors:  N J Talley; M Verlinden; D J Geenen; R B Hogan; D Riff; R W McCallum; R J Mack
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 6.  Type 1 diabetes and gastroparesis: diagnosis and treatment.

Authors:  William L Hasler
Journal:  Curr Gastroenterol Rep       Date:  2007-08

Review 7.  Nutrition therapy for diabetic gastroparesis.

Authors:  Diana Gentilcore; Deirdre O'Donovan; Karen L Jones; Michael Horowitz
Journal:  Curr Diab Rep       Date:  2003-10       Impact factor: 5.430

Review 8.  Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

Authors:  J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini
Journal:  Aliment Pharmacol Ther       Date:  2012-02-22       Impact factor: 8.171

9.  Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials.

Authors:  Mohammad Z Asha; Sundos F H Khalil
Journal:  Sultan Qaboos Univ Med J       Date:  2019-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.